> BiondVax wrapped up enrollment in the 224-person Phase IIb trial of its universal flu vaccine. The completion of recruitment sets Israel's BiondVax up to deliver top-line data on the candidate late in 2016 or early next year. BiondVax is looking to the Phase IIb trial to provide data on the safety and immunogenicity of the vaccine when it is administered prior to an avian influenza vaccine, a use case it sees helping make the most of stockpiles in the event of a pandemic. If all goes according to plan, BiondVax expects to have the candidate ready for Phase III in 2017 or 2018. Release
> MaxCyte (LON:MXCT) joined the small group of U.S. biotechs listed in London. The Maryland-based biotech raised £10 million ($14 million) through a listing on the city's AIM, a sum it will use to fund its advance into the development of mRNA CAR cell therapies. Specifically, MaxCyte, which started out providing technology to other companies, will put the money into IND-enabling studies and human clinical proof-of-concept trials in multiple oncology indications. Statement
> Auris Medical ($EARS) completed the recruitment of patients into a Phase III trial of its treatment for acute inner ear tinnitus. The 330-person study is designed to assess how AM-101, a small molecule N-methyl-D-aspartate receptor antagonist, compares to placebo in terms of changes in tinnitus loudness and Tinnitus Functional Index total score. Auris expects to have top-line data from the trial in August, by when it should also have completed enrollment in a second, parallel Phase III trial. Release
> Redx Pharma (LON:REDX) raised £10 million ($14.4 million) through a placement of shares. The proceeds, which were contributed by a mix of new institutional investors and existing shareholders, will go toward the furtherment of Redx's pipeline, notably the advance of its Porcupine program into the clinic. Redx expects the program, which is seen as potentially yielding treatments for cancer of the breast, pancreas, head and neck, to start clinical trials early next year. Statement
> Bone Therapeutics (EBR:BOTHE) reported initial efficacy data from a Phase IIa severe osteoporosis trial. After one year of treatment with PREOB, the first cohort of 7 patients experienced a drop in pain of 40% or more, a result Bone Therapeutics described as pronounced and clinically relevant. "These initial 12-month results are encouraging as they show that a single intravenous administration of PREOB, through a different mechanism-of-action, could have beneficial effects on pain and bone turnover in treatment-resistant osteoporosis patients," Bone Therapeutics CEO Enrico Bastianelli said in a statement. Release
> Baxalta Ventures and Medicxi Ventures led a €7 million ($7.8 million) Series A round in Gadeta, a Dutch biotech that is developing cancer immunotherapies based on gamma delta T cell receptors. The biotech is based on the work of the University Medical Center Utrecht's Dr. Jürgen Kuball to put the gamma delta receptor into alpha beta T cells, an approach Gadeta and its backers think may enable the creation of superior cancer immunotherapies. Gadeta is scheduled to start putting the concept through clinical testing early in 2017. FierceBiotech